These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 22916185

  • 21. Prevalence of human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus in three groups of populations at high risk of HIV infection in Amritsar (Punjab), Northern India.
    Jindal N, Arora U, Singh K.
    Jpn J Infect Dis; 2008 Jan; 61(1):79-81. PubMed ID: 18219142
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012.
    Li L, Assanangkornchai S, Duo L, McNeil E, Li J.
    PLoS One; 2014 Jan; 9(9):e106899. PubMed ID: 25203256
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R, Mahagna R, Maor Y, Kurnik D, Elbaz E, Halkin H, Olchovsky D, Ezra D, Almog S.
    Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
    [Abstract] [Full Text] [Related]

  • 26. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran.
    Imani R, Karimi A, Rouzbahani R, Rouzbahani A.
    East Mediterr Health J; 2008 Nov; 14(5):1136-41. PubMed ID: 19161086
    [Abstract] [Full Text] [Related]

  • 27. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.
    Bao Y, Larney S, Peacock A, Colledge S, Grebely J, Hickman M, Degenhardt L, Leung J.
    Int J Drug Policy; 2019 Aug; 70():87-93. PubMed ID: 31125802
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users.
    Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des Jarlais DC.
    J Acquir Immune Defic Syndr; 2002 Aug 01; 30(4):448-56. PubMed ID: 12138352
    [Abstract] [Full Text] [Related]

  • 30. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy.
    Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, Rezza G, Suligoi B, SerT Study Group.
    Ann Ist Super Sanita; 2010 Aug 01; 46(1):59-65. PubMed ID: 20348620
    [Abstract] [Full Text] [Related]

  • 31. [A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users].
    Wang YC, Xu SH, Li XH, Song AJ, Jia XR, Zhuang H.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Sep 01; 27(9):777-9. PubMed ID: 17299963
    [Abstract] [Full Text] [Related]

  • 32. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L.
    Lancet; 2011 Aug 13; 378(9791):571-83. PubMed ID: 21802134
    [Abstract] [Full Text] [Related]

  • 33. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
    Stark K, Müller R, Bienzle U, Guggenmoos-Holzmann I.
    AIDS; 1996 Mar 13; 10(3):311-7. PubMed ID: 8882671
    [Abstract] [Full Text] [Related]

  • 34. Prevalence of HCV & HBV infection amongst HIV seropositive intravenous drug users & their non-injecting wives in Manipur, India.
    Saha MK, Chakrabarti S, Panda S, Naik TN, Manna B, Chatterjee A, Detels R, Bhattacharya SK.
    Indian J Med Res; 2000 Feb 13; 111():37-9. PubMed ID: 10824464
    [Abstract] [Full Text] [Related]

  • 35. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
    Rhodes T, Platt L, Judd A, Mikhailova LA, Sarang A, Wallis N, Alpatova T, Hickman M, Parry JV.
    Int J STD AIDS; 2005 Nov 13; 16(11):749-54. PubMed ID: 16303071
    [Abstract] [Full Text] [Related]

  • 36. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.
    Miller M, Mella I, Moi H, Eskild A.
    J Acquir Immune Defic Syndr; 2003 Jul 01; 33(3):373-9. PubMed ID: 12843749
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal.
    Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC.
    J Urban Health; 2008 May 01; 85(3):309-22. PubMed ID: 18340537
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.